Literature DB >> 28250453

Thrombosis: Rivaroxaban, a cost-effective alternative for SVT?

Irene Fernández-Ruiz.   

Abstract

Entities:  

Year:  2017        PMID： 28250453     DOI： 10.1038/nrcardio.2017.27

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.

Authors:  Jan Beyer-Westendorf; Sebastian M Schellong; Horst Gerlach; Eberhard Rabe; Jeffrey I Weitz; Katja Jersemann; Kurtulus Sahin; Rupert Bauersachs
Journal:  Lancet Haematol       Date:  2017-02-16       Impact factor: 18.959
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.